| 18.24 0.58 (3.28%) | 04-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 21.89 | 1-year : | 25.57 |
| Resists | First : | 18.75 | Second : | 21.89 |
| Pivot price | 16.54 |
|||
| Supports | First : | 15.54 | Second : | 13.56 |
| MAs | MA(5) : | 17.13 |
MA(20) : | 16.08 |
| MA(100) : | 13.48 |
MA(250) : | 10.93 |
|
| MACD | MACD : | 0.6 |
Signal : | 0.4 |
| %K %D | K(14,3) : | 78 |
D(3) : | 66.3 |
| RSI | RSI(14): 64.5 |
|||
| 52-week | High : | 18.75 | Low : | 7.09 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ MDWD ] has closed below upper band by 8.9%. Bollinger Bands are 47.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 18.49 - 18.56 | 18.56 - 18.62 |
| Low: | 17.46 - 17.54 | 17.54 - 17.62 |
| Close: | 18.11 - 18.22 | 18.22 - 18.33 |
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
Thu, 25 Apr 2024
MediWound to Present New Data from EscharEx® Phase II Studies at Three Leading Wound Care Conferences - GlobeNewswire
Wed, 17 Apr 2024
Strength Seen in MediWound (MDWD): Can Its 14.3% Jump Turn into More Strength? - Yahoo Finance
Tue, 02 Apr 2024
MDWD Stock Quote Price and Forecast - CNN
Fri, 29 Mar 2024
Shareholders in MediWound (NASDAQ:MDWD) have lost 61%, as stock drops 11% this past week - Simply Wall St
Sun, 24 Mar 2024
MediWound Ltd. (NASDAQ:MDWD) Just Reported Full-Year Earnings: Have Analysts Changed Their Mind On The ... - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 9 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 25.7 (%) |
| Held by Institutions | 34.4 (%) |
| Shares Short | 163 (K) |
| Shares Short P.Month | 77 (K) |
| EPS | -0.75 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.43 |
| Profit Margin | -36 % |
| Operating Margin | -77 % |
| Return on Assets (ttm) | -16.7 % |
| Return on Equity (ttm) | -31.7 % |
| Qtrly Rev. Growth | -54.1 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 1.96 |
| EBITDA (p.s.) | -1.56 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -10 (M) |
| Levered Free Cash Flow | -10 (M) |
| PE Ratio | -24.32 |
| PEG Ratio | -0.1 |
| Price to Book value | 5.31 |
| Price to Sales | 9.26 |
| Price to Cash Flow | -16.55 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|